Akebia Announces Establishment of Rare Kidney Disease Pipeline
Provided By GlobeNewswire
Last update: Dec 1, 2025
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio
Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications
Read more at globenewswire.comNASDAQ:AKBA (12/18/2025, 10:50:02 AM)
1.665
+0.05 (+3.42%)
Find more stocks in the Stock Screener
